Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Investor's Business Daily on MSN21h
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 BillionRoche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
Novo Nordisk's new drug, CagriSema, showed promising results in reducing weight among overweight or obese type 2 diabetes patients. During the phase III REDEFINE 2 trial, participants experienced a 15 ...
Pharmaceutical manufacturer Novo ... weight management medicines, and 90% of Wegovy® patients with coverage pay $0 to $25 a month for Wegovy®,” said Dave Moore, president of Novo Nordisk ...
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...
Novo Nordisk ... for weight management medicines, and 90% of Wegovy patients with coverage pay $0 to $25 a month for Wegovy," said Dave Moore, president of Novo Nordisk's North America ...
We came across a bullish thesis on Novo Nordisk A/S (NYSE ... 1 category drugs that cater to blood sugar control and obesity management. NVO’s Wegovy & Ozempi have a market share of 45% compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback